---
reference_id: "PMID:28890134"
title: Modifiers of GRN-Associated Frontotemporal Lobar Degeneration.
authors:
- Wauters E
- Van Mossevelde S
- Van der Zee J
- Cruts M
- Van Broeckhoven C
journal: Trends Mol Med
year: '2017'
doi: 10.1016/j.molmed.2017.08.004
content_type: abstract_only
---

# Modifiers of GRN-Associated Frontotemporal Lobar Degeneration.
**Authors:** Wauters E, Van Mossevelde S, Van der Zee J, Cruts M, Van Broeckhoven C
**Journal:** Trends Mol Med (2017)
**DOI:** [10.1016/j.molmed.2017.08.004](https://doi.org/10.1016/j.molmed.2017.08.004)

## Content

1. Trends Mol Med. 2017 Oct;23(10):962-979. doi: 10.1016/j.molmed.2017.08.004.
Epub  2017 Sep 7.

Modifiers of GRN-Associated Frontotemporal Lobar Degeneration.

Wauters E(1), Van Mossevelde S(2), Van der Zee J(1), Cruts M(1), Van Broeckhoven 
C(3).

Author information:
(1)Neurodegenerative Brain Diseases, Center for Molecular Neurology, VIB, 
Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University 
of Antwerp, Antwerp, Belgium.
(2)Neurodegenerative Brain Diseases, Center for Molecular Neurology, VIB, 
Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University 
of Antwerp, Antwerp, Belgium; Department of Neurology and Memory Clinic, 
Hospital Network Antwerp Middelheim and Hoge Beuken, Antwerp, Belgium; 
Department of Neurology, Antwerp University Hospital, Edegem, Belgium.
(3)Neurodegenerative Brain Diseases, Center for Molecular Neurology, VIB, 
Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born-Bunge, University 
of Antwerp, Antwerp, Belgium. Electronic address: 
christine.vanbroeckhoven@molgen.vib-ua.be.

Heterozygous loss-of-function (LOF) mutations in the human progranulin gene 
(GRN) cause frontotemporal lobar degeneration (FTLD) by a mechanism of 
haploinsufficiency. Patients present most frequently with frontotemporal 
dementia, which is the second most common neurodegenerative dementia at young 
age. Currently, no disease-modifying therapies are available for these patients. 
Stimulating GRN protein expression or inhibiting its breakdown is an obvious 
therapeutic strategy, and is indeed the focus of current preclinical research 
and clinical trials. Multiple studies have demonstrated the heterogeneity in 
clinical presentation and wide variability in age of onset in patients carrying 
a GRN LOF mutation. Recently, this heterogeneity became an opportunity to 
identify disease modifiers, considering that these might constitute suitable 
targets for developing disease-modifying or disease-delaying therapies.

Copyright Â© 2017 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.molmed.2017.08.004
PMID: 28890134 [Indexed for MEDLINE]